Advanced non-small-cell lung cancer (NSCLC) treated with folinic acid (F), fluorouracil (FU), vincristine (O), and mitomycin-C (Mi), (F-FOMi).

Abstract

Thirty-one patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of folinic acid, fluorouracil, vincristine, and mitomycin (F-FOMi). Eight partial responses (26%), eight stable disease (26%), and 15 progressive disease (48%) were obtained. Patients with performance status (PS) 0-1 had a significantly better response rate than those with PS 2-3. Overall actuarial survival was 10 months. Toxicity was mild and mainly gastrointestinal with mucositis and diarrhea. F-FOMi seems to be comparable to regimens more widely used in the treatment of NSCLC.

• Authors: C Barone, A Astone, A Cassano, M R Noviello, T Fontana, E Ricevuto, A Grieco
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 15 Issue 6 Pg. 506-8 (Dec 1992) ISSN: 0277-3732 [Print] United States
• PMID: 1333168 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Mitomycin
• Vincristine
• Leucovorin
• Fluorouracil

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Female
• Fluorouracil (administration & dosage)
• Humans
• Leucovorin (administration & dosage)
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Mitomycin (administration & dosage)
• Vincristine (administration & dosage)